dicloxacillin Side Effects
Also known as: Dynapen
Analysis of 178 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
178
Death-Related
20
11.2% of reports
Hospitalizations
69
38.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 20 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| ABDOMINAL DISCOMFORT | 7 |
| DEATH | 7 |
| ACUTE KIDNEY INJURY | 3 |
| ARTHRITIS BACTERIAL | 2 |
| ATRIAL FIBRILLATION | 2 |
| CELLULITIS | 2 |
| CHEST PAIN | 2 |
| DEEP VEIN THROMBOSIS | 2 |
| FALL | 2 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 2 |
| HYPOTENSION | 2 |
| LIMB INJURY | 2 |
| PRODUCT USE IN UNAPPROVED INDICATION | 2 |
| SKIN ULCER | 2 |
| STAPHYLOCOCCAL SEPSIS | 2 |
| TACHYCARDIA | 2 |
| TRAUMATIC HAEMATOMA | 2 |
| WHEEZING | 2 |
| ABDOMINAL PAIN UPPER | 1 |
| ADVERSE DRUG REACTION | 1 |
Reactions in Hospitalization Reports
Top reactions in 69 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| ABDOMINAL DISCOMFORT | 9 |
| DYSPNOEA | 6 |
| PRURITUS | 6 |
| ACUTE KIDNEY INJURY | 5 |
| ANAEMIA | 5 |
| CELLULITIS | 5 |
| DIARRHOEA | 5 |
| RASH | 5 |
| VOMITING | 5 |
| BACK PAIN | 4 |
| CHEST PAIN | 4 |
| DECREASED APPETITE | 4 |
| DEEP VEIN THROMBOSIS | 4 |
| DRUG INTERACTION | 4 |
| FATIGUE | 4 |
| HYPOKALAEMIA | 4 |
| NAUSEA | 4 |
| OFF LABEL USE | 4 |
| PAIN IN EXTREMITY | 4 |
| PYREXIA | 4 |
Nearby — Related Medications
What the FAERS Data Reveals About dicloxacillin Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 178 voluntary reports linked to dicloxacillin and its brand equivalents (Dynapen), spanning 2004 through 2025. Of those, 20 (11.2%) listed death as an outcome and 69 (38.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 60% were female and 40% male; age distribution skews toward 45-64, with 50 reports in that bracket. The single most reported reaction is suspected transmission of an infectious agent via product with 13 submissions, followed by rash and fatigue.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.